Node Not Found: -adriamycin-Node Not Found: - rituxan-Node Not Found: - marqibo-Node Not Found: -xospata-Node Not Found: -lemtrada-Node Not Found: - imbruvica-Node Not Found: - zydelig-Node Not Found: - medrol-Node Not Found: - arzerra-Node Not Found: - rituxan-Node Not Found: - venclexta-Node Not Found: -darzalex-Node Not Found: - revlimid-Node Not Found: - pomalyst-Node Not Found: -lipodox-Node Not Found: - gemzar-Node Not Found: - lynparza-Node Not Found: - hycamtin- Meetings - The ASCO Post
Advertisement

Advertisement

2019 Best of ASCO

adriamycin
rituxan
marqibo

Rituximab Maintenance Adds No Benefit for Patients With Diffuse Large B-Cell Lymphoma

After treatment with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone), rituximab maintenance therapy seems to provide no additional benefit for patients with diffuse larg...

xospata

ADMIRAL Study Finds Gilteritinib Effective Across Mutation Cohorts of Acute Myeloid Leukemia

The novel FLT3 inhibitor gilteritinib prolonged survival in patients with FLT3-mutated relapsed or refractory acute myeloid leukemia (AML) across all mutation cohorts, including NPM1, DNMT3A, DNMT3A/N...

lemtrada
imbruvica
zydelig
medrol
arzerra
rituxan
venclexta

Final Results of RESONATE Trial Show Long-Term Benefit of Ibrutinib in Relapsed or Refractory CLL

After 6 years of follow-up, extended treatment with ibrutinib showed sustained progression-free survival benefit and depth of response in patients with relapsed or refractory chronic lymphocytic leu...

darzalex
revlimid
pomalyst

Benefits Reported With Addition of Isatuximab to Pomalidomide and Dexamethasone in Resistant Multiple Myeloma

In patients with relapsed or refractory multiple myeloma, isatuximab in combination with pomalidomide and low-dose dexamethasone nearly doubled progression-free survival when compared with pomalidomid...

lipodox
gemzar
lynparza
hycamtin

Olaparib Monotherapy Improves Outcomes in BRCA-Mutated, Platinum-Sensitive Relapsed Ovarian Cancer

Compared with treatment with nonplatinum-based chemotherapy, monotherapy with the PARP (poly [ADP ribose] polymerase) inhibitor olaparib led to statistically significant and clinically relevant impr...

Breast Cancer
Survivorship

Pregnancy Appears Safe After Treatment for Breast Cancer in Patients With BRCA Mutations

Pregnancy after breast cancer appears to be safe in patients with germline BRCA mutations—and particularly among those with BRCA1 mutations—according to new research. Limited data are available on the...

Supportive Care
Symptom Management

Study Explores Efficacy of Lower-Dose Olanzapine in Combination With Standard Antiemetic Regimen

Olanzapine at a 5-mg dose, when combined with aprepitant, palonosetron, and dexamethasone, significantly reduced the risk of delayed nausea and vomiting in patients receiving cisplatin-based chemother...

Advertisement

Advertisement



Advertisement